

**Combined Shareholders' Meeting of 27 May 2015**  
**Availability of documentation for the Shareholders' Meeting**

**Paris (France), 6 May 2015** – The Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen SA to be held on Wednesday 27 May 2015 at 3 pm (Paris time) at La Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d'Iéna, 75116 Paris, France.

The preliminary notice of meeting containing the agenda and the proposed resolutions has been published in the *Bulletin des Annonces Légales Obligatoires* (BALO) dated 15 April 2015 and is available on Ipsen's website at the following address: [www.ipsen.com](http://www.ipsen.com).

Documents and information relating to this Meeting will be made available to shareholders under the conditions provided for by legal and regulatory provisions in force.

In accordance with applicable regulatory provisions:

- Registered shareholders can, until the fifth day (inclusive) before the Meeting, request from the Company supply of the said documents, including at their request, by way of an electronic mail. For holders of bearer shares, the exercise of this right is subject to the presentation of a certificate of attendance in the bearer share accounts kept by the empowered intermediary;
- All shareholders can consult these documents at the Company's headquarters.

**About Ipsen**

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urologyoncology. Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com).

**For further information:**

**Media**

**Didier Véron**

Senior Vice President, Public Affairs and Communication

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

Email: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

**Brigitte Le Guennec**

Corporate External Communication

Tel. : +33 (0)1 58 33 51 17

Fax : 01 58 33 50 58

Email : [brigitte.le.guennec@ipsen.com](mailto:brigitte.le.guennec@ipsen.com)

**Financial Community**

**Stéphane Durant des Aulnois**

Vice President, Investor Relations

Tel.: +33 (0)1 58 33 60 09

Fax: +33 (0)1 58 33 50 63

E-mail: [stephane.durant.des.aulnois@ipsen.com](mailto:stephane.durant.des.aulnois@ipsen.com)

**Thomas Peny-Coblentz, CFA**

Investor Relations Deputy Director

Tel.: +33 (0)1 58 33 56 36

Fax: +33 (0)1 58 33 50 63

Email: [thomas.peny-coblentz@ipsen.com](mailto:thomas.peny-coblentz@ipsen.com)